View Older Stories

Feb 5, 2026 06:42AM H.C. Wainwright Starts Incyte (INCY) at Buy

Jan 30, 2026 09:29AM Incyte gets positive CHMP opinion for anal cancer drug Zynyz

Jan 20, 2026 05:36AM Wells Fargo Downgrades Incyte (INCY) to Equal Weight

Jan 13, 2026 08:50AM Incyte (INCY) PT Raised to $128 at TD Cowen

Jan 5, 2026 01:33PM Stifel Reiterates Buy Rating on Incyte (INCY)

Jan 5, 2026 12:10PM Incyte (INCY) PT Raised to $129 at Leerink Partners

Jan 5, 2026 07:30AM Incyte drug trial meets primary endpoint for lymphoma treatment

Dec 22, 2025 05:40AM Japan approves Incyte's Minjuvi for follicular lymphoma treatment

Dec 17, 2025 11:20AM INCYTE wins European approval for Minjuvi cancer treatment

Dec 11, 2025 05:59AM RBC Capital Reiterates Sector Perform Rating on Incyte (INCY)

Dec 9, 2025 05:12AM Incyte's (INCY) 989 is First-in-Class, Has Broad Clinical Utility - Citizens

Dec 8, 2025 04:30PM Incyte presents data showing 90% response rate for blood cancer drug

Dec 8, 2025 06:20AM Incyte (INCY) PT Raised to $128 at Leerink Partners

Dec 8, 2025 05:18AM Incyte (INCY) PT Raised to $118 at BofA Securities

Dec 8, 2025 04:53AM Mizuho Upgrades Incyte (INCY) to Outperform 'on Higher Confidence in Pipeline'

Dec 8, 2025 02:53AM FDA grants breakthrough therapy designation to INCA033989 for blood cancer

Dec 8, 2025 02:53AM Incyte reports phase 1 data for myelofibrosis drug INCA033989

Nov 17, 2025 03:57AM CHMP recommends Incyte's Minjuvi for relapsed follicular lymphoma

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 4, 2025 07:01AM Prelude Therapeutics secures $60M from Incyte option deal

Oct 29, 2025 09:59AM Incyte (INCY) PT Raised to $101 at TD Cowen; 'Q3 Beats Across All Franchises'

Oct 28, 2025 03:29PM Incyte (INCY) PT Raised to $84 at Oppenheimer

Oct 28, 2025 10:31AM Incyte (INCY) PT Raised to $109 at BofA Securities

Oct 28, 2025 07:02AM Incyte (INCY) Tops Q3 EPS by 67c; raises guidance

Oct 14, 2025 09:46AM Incyte (INCY) PT Raised to $76 at UBS

Oct 8, 2025 02:56AM Oppenheimer Downgrades Incyte (INCY) to Perform

Oct 3, 2025 04:03PM Incyte appoints Thomas Tray as principal financial officer

Sep 24, 2025 05:03AM Incyte (INCY) PT Raised to $81 at RBC Capital

Sep 22, 2025 04:39AM Incyte (INCY) PT Raised to $115 at Stifel

Sep 18, 2025 04:15AM Citizens JMP Reiterates Market Perform Rating on Incyte (INCY)

Sep 3, 2025 09:15AM Incyte launches awareness campaign for hidradenitis suppurativa patients

Aug 1, 2025 03:59AM Barclays Starts Incyte (INCY) at Overweight

Jul 30, 2025 08:29AM Incyte (INCY) PT Raised to $60 at BMO Capital

Jul 30, 2025 07:59AM Incyte (INCY) PT Raised to $72 at RBC Capital

Jul 29, 2025 04:12PM Incyte (INCY) PT Raised to $79 at Truist Securities

Jul 29, 2025 04:06PM Incyte (INCY) PT Raised to $89 at TD Cowen

Jul 29, 2025 07:02AM Incyte (INCY) Misses Q2 EPS by 140c

Jul 24, 2025 05:02PM Incyte to present cancer drug data at ESMO Congress 2025

Jul 15, 2025 09:44AM Incyte (INCY) PT Raised to $62 at UBS

Jun 26, 2025 12:27PM William Blair Comments on Incyte (INCY) CEO Transition

Jun 26, 2025 10:36AM Citi Comments Incyte (INCY) New CEO

Jun 26, 2025 09:45AM Incyte (INCY) new CEO sparks chatter

Jun 26, 2025 09:18AM Incyte (INCY) CEO change timing 'feels right' - Stifel

Jun 26, 2025 07:30AM Incyte (INCY) Appoints Bill Meury as Next CEO

Jun 20, 2025 04:31PM Incyte (INCY) announces that FDA extends review for Ruxolitinib cream

Jun 18, 2025 03:39PM Incyte (INCY) Announces FDA Approval of Monjuvi in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Jun 18, 2025 03:38PM FDA approves Incyte's tafasitamab-cxix for relapsed or refractory follicular lymphoma

Jun 16, 2025 07:55AM Incyte (INCY): Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Jun 16, 2025 06:11AM Oppenheimer Reiterates Outperform Rating on Incyte (INCY)

Jun 16, 2025 04:48AM Incyte (INCY) PT Raised to $82 at Jefferies

View Older Stories